ArticleCureus2025
Evaluation of the Ki-67 Labeling Index as a Prognostic Stratification Factor in Non-High-Risk Gastrointestinal Stromal Tumors.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim This study aimed to evaluate the Ki-67 labeling index (LI) as a prognostic factor for recurrence in patients with non-high-risk gastrointestinal stromal tumors (GISTs), as defined by the modified NIH risk classification. Patients and methods In this retrospective study, 72 patients with GISTs who had undergone complete tumor resection and received no adjuvant therapy until recurrence were included. The Ki-67 LI and mitotic count were assessed in hotspot sections of each tumor. Results According to the modified NIH risk classification, 54 tumors were categorized as non-high-risk (very low-, low-, or intermediate-risk) and 18 as high-risk. During follow-up, recurrence occurred in seven (13.0%) non-high-risk cases and nine (50.0%) high-risk cases. Receiver operating characteristic analysis for recurrence identified an optimal Ki-67 LI cutoff of 3.0% for non-high-risk GISTs. Among non-high-risk cases, recurrence occurred in seven of 26 (26.9%) with Ki-67 LI ≥ 3.0%, whereas none of the 28 with Ki-67 LI < 3.0% experienced recurrence. Kaplan-Meier analysis of recurrence-free survival, stratified by this cutoff, showed significantly worse outcomes for the non-high-risk group with Ki-67 LI ≥ 3.0%. Conclusions These findings suggest that Ki-67 LI may serve as a useful stratification factor in patients with non-high-risk GISTs. In particular, applying Ki-67 LI stratification may help identify non-high-risk patients who require closer surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.